Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

ABSTRACT:

Importance

Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for PCNSL, but no consensus exists on the optimal conditioning regimens.

Objective

To assess the outcomes in patients with PCNSL undergoing AHCT with the 3 most commonly used conditioning regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU), and carmustine/etoposide/cytarabine/melphalan (BEAM).

Design, setting, and participants

This observational cohort study used registry data from the Center for International Blood and Marrow Transplant Research registry. The Center is a working group of more than

SUBMITTER: Scordo M 

PROVIDER: S-EPMC8283558 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature